Isomorphic Labs was founded in 2021 as a spin-out from Google DeepMind, led by Demis Hassabis, with the conviction that biology can be understood and engineered as an information-processing system. The company sits at the intersection of frontier machine learning and structural biology, building on the breakthrough of AlphaFold, the protein-structure-prediction model that solved a decades-old grand challenge. With the release of AlphaFold 3 in 2024, developed jointly with Google DeepMind, the platform expanded beyond proteins to predict the structure and interactions of nearly all of life's molecules, including ligands, nucleic acids, and small molecules relevant to drug design.
The heart of Isomorphic's strategy is a next-generation AI drug-design engine that aims to model molecular interactions with enough accuracy to dramatically increase the success rate of preclinical programs. Rather than relying solely on costly, slow wet-lab experimentation, the company uses generative and predictive models to propose and prioritize candidate molecules computationally, then validate them experimentally in a tight design-make-test loop.
Isomorphic operates a dual business model: strategic research collaborations with large pharmaceutical companies and a growing portfolio of internally owned therapeutic programs. It has signed multi-billion-dollar collaboration agreements with Eli Lilly and Novartis, each carrying upfront payments, milestone payments, and royalties tied to programs across multiple disease targets. In March 2025, the company raised its first external funding round of $600 million, led by Thrive Capital with participation from GV and follow-on capital from Alphabet, to accelerate development of its drug-design model and advance therapeutic programs toward clinical testing.
The company's vision is to one day solve disease using a fully AI-first approach, where computation guides every stage from target identification to candidate optimization. By concentrating world-class AI talent alongside drug-discovery scientists, Isomorphic positions itself as one of the most ambitious and well-capitalized bets in the TechBio sector.